Gastroenterology

The treatment resulted in a significant reduction in expression of genes representing T & B lymphocytes, plasma cells/plasmablasts, and myeloid cells.

IDSA and SHEA released 3 new evidence-based recommendations for treating CDI.

Only 5 patients treated with antibiotic prophylaxis developed bacteremia.

Diabetes, obesity, and older age are considered main risk factors that yield non-responses to different HBV vaccines.

Nearly half of all never C difficile cases are found in nursing home communities.

The overall 90-day cumulative incidences of a first CDI episode was 1.9%.

Researchers found no difference between the risk of death or mechanical ventilation based on different IBD Treatments.

Strain typing data is not often available to assess whether recurrence is due to CDI relapse or reinfection.

It could take up to 10 years to develop new treatments for inflammatory bowel disease.

Many gastroenterologists have utilized telemedicine during the ongoing COVID-19 pandemic.

The plan, developed in 2016, has resulted in reductions of most oral antibiotic uses, for both in-hospital and out-of-hospital settings.

Both the Mediterranean Diet and the Specific Carbohydrate diet achieved nearly 50% symptomatic remission in patients with IBD.

Small molecule treatments have been historically effective at treating IBD.

A team of investigators stress the impact of the disease on patients as mortality rates grow worldwide.

There was no significant difference in performance between the model with only bile acids compared to models with bile acids and clinical variables.

Hematopoietic stem cell transplant is generally associated with increased C difficile infection risk.

Sustained virologic response following direct acting antiviral treatment substantially reduced the all-cause mortality rate in patients with HCV.

More than half of the patients in the study were treated for inflammatory bowel disease with infliximab.

The expansion for sofosbuvir/velpatasvir is supported by phase 2 data showing an 83% sustained virologic response or cure rate among patients as young as 3 years old.

Patients included in the study had a median of 3 prior CDI episodes and 4 risk factors for recurrent infections.

The UNITI studies have shown ustekinumab is effective at inducing and maintaining clinical remission in Crohn’s disease patients.

Using both tests to screen for colorectal cancer was more effective than just using colonoscopies alone.

Direct-acting antivirals has increased the need to treat children HCV patients before they begin to engage in dangerous behaviors.

Vedolizumab treatment was associated with lower IMC recurrence rate after ICI resumption.

Seres expects to move forward with plans for SER-109 as a novel treatment for CDI.